Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients
NCT ID NCT07674498
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standard therapy, looking at markers of immune cell aging and exhaustion. The goal is to combine immune profiles with frailty assessments to better personalize treatment for older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors predict which older patients will benefit most from advanced immunotherapies, leading to more personalized treatment plans.
What could go wrong
This is an observational study, not a treatment trial. It aims to gather information, not test a new therapy, so it will not directly improve outcomes for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Saint-Pierre
NOT_YET_RECRUITINGBrussels, Brussels Capital, 1000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Jules Bordet
RECRUITINGAnderlecht, Brussels Capital, 1070, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
institut roi albert II
NOT_YET_RECRUITINGWoluwe-Saint-Lambert, Brussels Capital, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••